Synaptogenix (NASDAQ:TAOX) Posts Quarterly Earnings Results

Synaptogenix (NASDAQ:TAOX) issued its quarterly earnings data on Tuesday. The company reported $1.03 earnings per share for the quarter, FiscalAI reports. The company had revenue of ($2.46) million for the quarter.

Synaptogenix Trading Up 6.0%

NASDAQ TAOX opened at $5.69 on Wednesday. The company has a fifty day simple moving average of $4.65 and a two-hundred day simple moving average of $5.82. The stock has a market cap of $42.38 million, a P/E ratio of -0.28 and a beta of 1.99. Synaptogenix has a 12-month low of $1.84 and a 12-month high of $11.98.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on TAOX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Synaptogenix in a report on Thursday, January 22nd. Wall Street Zen upgraded shares of Synaptogenix from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.